NewsAI-assisted

EktaH Advances NKS-3 Obesity Drug into Phase IIa After Securing €2.4 Million Funding

EktaH enrolls first patient in Phase IIa obesity trial in Tunisia, backed by €2.4M in new funding for NKS-3.

Vaibhavi M.
By Vaibhavi M.
Subject Matter Expert · Pharma Now
Nov 18, 20262 min read
EktaH Advances NKS-3 Obesity Drug into Phase IIa After Securing €2.4 Million Funding
AI-assisted reporting
Reviewed by Vaibhavi M., Subject Matter Expert · Pharma Now
70/ 100
Trust score
Moderate confidence

With the first patient now enrolled in a Phase IIa trial in Tunisia, EktaH is committing clinical-stage resources to NKS-3 at a moment when the GLP-1 class has reset expectations across the obesity pipeline. For clinical supply chain leads and QA directors supporting small European biotechs, the geography of this trial raises immediate questions around investigational medicinal product logistics, local GMP equivalence, and regulatory alignment with ICH Q10 quality system expectations.

The French biotech secured €2.4 million in funding to underpin the Phase IIa programme, which targets weight loss as the primary endpoint. The trial's Tunisia site introduces a cross-border clinical supply dynamic that requires careful attention to import licensing, cold-chain qualification, and comparability of site GMP standards against EU norms. For QA leads overseeing investigational product release, the distance between the manufacturing origin and the trial site demands documented bridging of quality oversight responsibilities.

NKS-3 enters a development landscape where differentiation from established GLP-1 receptor agonists will be scrutinised at every regulatory interaction. EktaH has not disclosed the mechanism of action in available source material, which limits early assessment of how the compound's profile positions against the dominant class. What is clear is that a €2.4 million raise is a lean resource base for a Phase IIa programme that must generate efficacy and safety data sufficient to attract larger development partners or justify a Phase IIb design.

For contract development and manufacturing organisations tracking early-stage obesity entrants, NKS-3 represents the category of asset that typically requires flexible clinical batch manufacturing arrangements, with process validation commitments deferred until proof-of-concept data mature. The clinical supply agreement structure at this stage will carry weight when EktaH moves toward any out-licensing conversation or seeks a larger clinical manufacturing partner ahead of Phase IIb.

The measurable checkpoint ahead is Phase IIa data readout, which will determine whether NKS-3's efficacy signal justifies the expanded programme EktaH has indicated it is preparing.

Source: Media4Growth via Indian Pharma Post, 17 November 2026.

Read the original release ↗
TopicsNews
Vaibhavi M.
Written by
Vaibhavi M.
Subject Matter Expert · Pharma Now

Reporting on the science, business and regulation shaping the pharmaceutical industry.

Discussion

Loading discussion…

More from Pharma News

All stories →